𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The aggresome pathway as a target for therapy in hematologic malignancies

✍ Scribed by Tiffany Simms-Waldrip; Agustin Rodriguez-Gonzalez; Tara Lin; Alan K. Ikeda; Cecilia Fu; Kathleen M. Sakamoto

Book ID
116988362
Publisher
Elsevier Science
Year
2008
Tongue
English
Weight
242 KB
Volume
94
Category
Article
ISSN
1096-7192

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Mammalian target of rapamycin inhibition
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
✍ Amit Panwalkar; Srdan Verstovsek; Francis J. Giles πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 588 KB

## Abstract The mammalian target of rapamycin (mTOR) is a downstream effector of the phosphatidylinositol 3‐kinase (PI3K)/Akt (protein kinase B) signaling pathway, which mediates cell survival and proliferation. mTOR regulates essential signal‐transduction pathways, is involved in the coupling of g

Mammalian target of rapamycin inhibition
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
✍ Corey Cutler; Joseph H. Antin πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 32 KB

P anwalkar and colleagues present a very complete overview on the evolving role of mammalian target of rapamycin (mTOR) inhibitors in the treatment of both hematologic and nonhematologic malignancies. We wish to clarify selected statements made by the authors. We would like to point out that all mT